Kalaris Therapeutics, Inc. (KLRS)
4.08
-0.07
(-1.69%)
USD |
NASDAQ |
Aug 24, 16:00
4.08
0.00 (0.00%)
After-Hours: 20:00
Kalaris Therapeutics Shareholders Equity (Quarterly) : 57.67M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 57.67M |
| March 31, 2026 | 68.56M |
| December 31, 2025 | 78.81M |
| September 30, 2025 | 41.86M |
| June 30, 2025 | 53.12M |
| March 31, 2025 | 63.87M |
| December 31, 2024 | -96.62M |
| September 30, 2024 | 121.12M |
| June 30, 2024 | 120.29M |
| March 31, 2024 | 120.44M |
| December 31, 2023 | 145.78M |
| September 30, 2023 | 195.33M |
| June 30, 2023 | 229.11M |
| March 31, 2023 | 193.53M |
| Date | Value |
|---|---|
| December 31, 2022 | 224.52M |
| September 30, 2022 | 253.23M |
| June 30, 2022 | 158.14M |
| March 31, 2022 | 191.68M |
| December 31, 2021 | 225.27M |
| September 30, 2021 | 267.30M |
| June 30, 2021 | 302.47M |
| March 31, 2021 | 330.37M |
| December 31, 2020 | 353.06M |
| September 30, 2020 | 373.90M |
| June 30, 2020 | 101.83M |
| March 31, 2020 | 113.11M |
| December 31, 2019 | 121.62M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Replimune Group, Inc. | 105.64M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 99.54M |
| Total Liabilities (Quarterly) | 41.87M |
| Debt to Equity Ratio | 0.0243 |
| Current Ratio | 10.92 |
| Net Debt Paydown Yield | -0.29% |